SCTB14
Phase 3Small molecule
SCTB14 is one of 40 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1SSGJ-707
SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
Carboplatin Plus Paclitaxel
BayerPhase 3
SCTB14
SSinocelltech Ltd.
Phase 3
HLX17
Shanghai Henlius BiotechPhase 3
Remeron
OOrganon and Co
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Malignant Solid Tumours1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCTB14. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSinocelltech Ltd.